388 related articles for article (PubMed ID: 25671130)
1. Epstein-barr virus vaccines.
Cohen JI
Clin Transl Immunology; 2015 Jan; 4(1):e32. PubMed ID: 25671130
[TBL] [Abstract][Full Text] [Related]
2. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
[TBL] [Abstract][Full Text] [Related]
3. Vaccine Development for Epstein-Barr Virus.
Cohen JI
Adv Exp Med Biol; 2018; 1045():477-493. PubMed ID: 29896681
[TBL] [Abstract][Full Text] [Related]
4. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
5. The need and challenges for development of an Epstein-Barr virus vaccine.
Cohen JI; Mocarski ES; Raab-Traub N; Corey L; Nabel GJ
Vaccine; 2013 Apr; 31 Suppl 2(0 2):B194-6. PubMed ID: 23598481
[TBL] [Abstract][Full Text] [Related]
6. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
Front Immunol; 2018; 9():932. PubMed ID: 29765376
[TBL] [Abstract][Full Text] [Related]
7. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
[TBL] [Abstract][Full Text] [Related]
8. Progress in EBV Vaccines.
van Zyl DG; Mautner J; Delecluse HJ
Front Oncol; 2019; 9():104. PubMed ID: 30859093
[TBL] [Abstract][Full Text] [Related]
9. A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits.
Escalante GM; Foley J; Mutsvunguma LZ; Rodriguez E; Mulama DH; Muniraju M; Ye P; Barasa AK; Ogembo JG
Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32268575
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus vaccine development: a lytic and latent protein cocktail.
Lockey TD; Zhan X; Surman S; Sample CE; Hurwitz JL
Front Biosci; 2008 May; 13():5916-27. PubMed ID: 18508632
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic and therapeutic strategies for Epstein-Barr virus-associated diseases: emerging strategies for clinical development.
Dasari V; Sinha D; Neller MA; Smith C; Khanna R
Expert Rev Vaccines; 2019 May; 18(5):457-474. PubMed ID: 30987475
[TBL] [Abstract][Full Text] [Related]
12. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
[TBL] [Abstract][Full Text] [Related]
13. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
Perez EM; Foley J; Tison T; Silva R; Ogembo JG
Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
[TBL] [Abstract][Full Text] [Related]
14. An Overview of Epstein-Barr Virus: from Discovery to Future Directions for Treatment and Prevention.
Andersson J
Herpes; 2000 Oct; 7(3):76-82. PubMed ID: 11867007
[TBL] [Abstract][Full Text] [Related]
15. The Potential for EBV Vaccines to Prevent Multiple Sclerosis.
Maple PA; Ascherio A; Cohen JI; Cutter G; Giovannoni G; Shannon-Lowe C; Tanasescu R; Gran B
Front Neurol; 2022; 13():887794. PubMed ID: 35812097
[TBL] [Abstract][Full Text] [Related]
16. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
17. The Role of Epstein-Barr Virus in Cervical Cancer: A Brief Update.
Vranic S; Cyprian FS; Akhtar S; Al Moustafa AE
Front Oncol; 2018; 8():113. PubMed ID: 29719817
[TBL] [Abstract][Full Text] [Related]
18. Differences in the Epstein-Barr Virus gp350 IgA Antibody Response Are Associated With Increased Risk for Coinfection With a Second Strain of Epstein-Barr Virus.
Smith NA; Baresel PC; Jackson CL; Ogolla S; Toko EN; Heit S; Piriou E; Sumba OP; Middeldorp JM; Colborn KL; Rochford R
J Infect Dis; 2019 Feb; 219(6):955-963. PubMed ID: 30312417
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Epstein-Barr Virus infection in immunocompromised patients.
Pociupany M; Snoeck R; Dierickx D; Andrei G
Biochem Pharmacol; 2024 May; 225():116270. PubMed ID: 38734316
[TBL] [Abstract][Full Text] [Related]
20. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases.
Xu J; Ahmad A; Blagdon M; D'Addario M; Jones JF; Dolcetti R; Vaccher E; Prasad U; Menezes J
Int J Cancer; 1998 Oct; 79(5):481-6. PubMed ID: 9761116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
